J

Johnson & Johnson

Makes prescription drugs and medical devices

Senior Plastic Surgery Sales Representative - Aesthetics and Reconstruction

Full-TimeUpdated on 10/27/2026Deadline 11/13/26
$56k - $89.7k+ Sales commissions/incentives + Long-term incentive program
Mid, Senior
Bachelor's
Los Angeles, CA, USA+1 moreMore locations: Pasadena, CA, USA
In PersonField-based role supporting the Los Angeles territory.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree is required.
  • At least 4 years of total work experience is required.
  • At least 4 years of outside sales experience is required.
  • Sustained performance overseeing $1.5 million to $3.5 million in annual year-over-year sales in 3 out of 4 years is required.
Responsibilities
  • Demonstrate the proper surgical use of products to physicians.
  • Handle customer product questions and objections using the company's sales training methodology.
  • Maintain and expand current accounts, build new accounts, develop customer relationships, and meet product sales quotas.
  • Execute the selling cycle professionally, ethically, and persuasively to move customers to action.
  • Operate within defined budgetary limits.
  • Communicate business-related issues or opportunities to the next management level.
  • Ensure personal and company compliance with applicable federal, state, and local regulations, policies, and procedures.
  • Perform other duties as assigned.
  • Develop customers and manage accounts by differentiating products and using a consultative sales approach, including pre-call planning, assessing customer needs, handling objections, presenting visual aids, closing, and follow-up.
  • Build strong customer relationships, hold customers accountable to commitments, and maintain a high level of customer interaction.
  • Manage account growth; understand the business environment and products; educate customers and understand their circumstances, needs, and concerns; motivate customers to become product advocates; build strategic working relationships; develop and service key opinion leaders; and allocate marketing programs.
  • Position the Mentor portfolio effectively for augmentation and reconstruction settings.
  • Meet productivity goals across the product portfolio.
  • Manage and execute activity across private practice, surgery center, and hospital call points; assess territory metrics; and develop and implement territory business plans.
  • Implement and promote marketing programs in private practice settings.
  • Meet sales training requirements set by senior leadership and administrative requirements and timelines set by the Regional Manager.
  • Complete consignment audits before deadlines and maintain the territory within regional travel and budget parameters.
  • Apply market knowledge and technical fluency across the Mentor and competitive product portfolios, understand breast anatomy, and demonstrate expertise in supporting studies and materials.
  • Understand how individual tactics support overall strategy, execute the marketing plan across the product portfolio, and articulate strategy to customers, management, and team members.
Desired Qualifications
  • Surgical sales experience is preferred.
  • Knowledge of clinical and surgical techniques and procedures, and medical terminology, is preferred.
  • At least 4 years of sales experience, including a documented history of 2 or more years of sales success in a medical device sales environment, is preferred.
  • Experience selling to surgeons in an operating room environment and/or calling on plastic surgeons is preferred.
  • Aesthetics sales experience and experience calling on plastic surgeons is preferred.
  • Ability to identify decision makers and influence decisions.
  • Ability to manage and prioritize workload, multitask, and manage a diverse mix of issues, responsibilities, and challenges.
  • Ability to manage budgets and expenses and execute plans.
  • Strong computer skills.
  • Ability to function effectively in a high-performance team and adapt to a rapidly changing environment.
  • Strong organizational and prioritization skills.
  • Ability to communicate scientific and clinical product features and benefits.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
Associated Press
Oct 27th, 2026
Pomerantz investigates Johnson & Johnson after 5.73% share drop on talc charges and MedTech miss

Pomerantz LLP is investigating whether Johnson & Johnson (J&J) and some of its officers or directors engaged in securities fraud or other unlawful business practices. The law firm advises affected investors to contact Danielle Peyton at [email protected]. On October 13, 2026, J&J reported third-quarter GAAP net earnings of $210 million, or $0.09 per share. Multi-billion dollar special charges tied to its talc litigation settlement weighed on the result. Its MedTech segment grew only 2.5% to $8.64 billion, a second straight revenue miss. J&J cited pricing constraints in China and disruption in the Middle East. The stock fell $15.12, or 5.73%, to close at $248.61 that day.

Yahoo Finance
Oct 27th, 2026
J&J sees $34.7M net ETF outflow, extending selling streak to four days

ETFs sold a net $34.7 million of Johnson & Johnson stock on Friday, October 23, extending a four-day run of net selling. SPY led the move, cutting $34.6 million, or 0.44% of its stake. XLV sold $24.6 million and DIA $6.3 million. More funds bought than sold, with 26 ETFs adding shares and 17 cutting them, but their purchases were smaller. Net outflows were $55.2 million on October 22, $54.1 million on October 21, and $19.8 million on October 20. A net inflow of $38.1 million came on October 19. Johnson & Johnson has a market cap of $641.1 billion. It reported $99.35 billion in trailing-12-month revenue, up 7.0% over one year.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.